Psoriasis is a chronic skin disease caused by immune disorder. The chronic skin inflammation involves inflammatory molecules that are released from T lymphocytes and keratinocytes. Therefore, developing an anti-inflammatory therapy that is suitable for long-term treatment is needed. Electrical stimulation induces biological responses by modulating intracellular signaling pathways. Our previous studies showed that the optimized combination treatment of mild electrical stimulation (MES, 0.1-millisecond; ms, 55-pulses per second; pps) and heat shock (HS, 42°C) modulates inflammatory symptoms of metabolic disorders and chronic kidney disease in mice models and clinical trials. Here, we investigated the effect of MES+HS treatment on imiquimod-induced psoriasis mouse model. Topical application of imiquimod cream (15 mg) to mice ear induced keratinocyte hyperproliferation and psoriasis-like inflammation. In MES+HS-treated mice, imiquimod-induced skin hyperplasia was significantly decreased. MES+HS treatment reduced the protein expression of IL-17A and the infiltration of CD3-positive cells in lesioned skin. In addition, MES+HS-treated mice had decreased mRNA expression level of antimicrobial molecules (S100A8 and Reg3γ) which aggravate psoriasis. In IL-17A-stimulated HaCaT cells, MES+HS treatment significantly lowered the mRNA expression of aggravation markers (S100A8, S100A9 and β-defensin2). Taken together, our study suggested that MES+HS treatment improves the pathology of psoriasis via decreasing the expression of inflammatory molecules.
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TSUREKAWA ET Al. cytokines such as interleukin-17A (IL-17A) and IL-22 from T lymphoid cells stimulate keratinocytes by direct or indirect mechanisms. [3, 4] Cytokine-stimulated keratinocytes themselves exacerbate inflammation and proliferation by releasing antimicrobial proteins such as S100 proteins and regenerating islet-derived protein 3 (Reg3). [5, 6] Collectively, these studies demonstrate that the crosstalk between T lymphoid cells and keratinocytes in skin inflammation involves positive feedback loop. At present, development of new drugs including biological agents provides drug options for the treatment of psoriasis. [7, 8] However, these drugs are not necessarily suitable for long-term treatment because of their risk of side effects and high cost. Therefore, it is important to develop a novel therapeutic approach which is highly effective and tolerable for chronic pathology.
Skin covers our entire body and has the essential role of receiving external stimuli. Although excessive stimuli have harmful effects, basically they are needed to maintain the skin homeostasis. [9] Previous studies showed that electrical stimulation has beneficial effect on wound healing and skin barrier formation. [10, 11] We have comprehensively studied the biological effects of optimized combination treatment with mild electrical stimulation (MES) and heat
shock (HS). MES+HS treatment not only improved insulin resistance
and inflammation in diabetes mouse models, but also had antiinflammatory effects on chronic kidney disease mouse model. [12] [13] [14] The therapeutic effects of combination treatment (MES+HS) are higher than those of MES alone or HS alone. In addition, we showed that MES+HS exerts biological effects via activation of intracellular signaling pathways such as p53 and LKB1-AMPK axis. [15, 16] In clinical studies for subjects with type 2 diabetes mellitus and metabolic syndrome, MES+HS treatment significantly ameliorated the insulin resistance and inflammatory parameters without any adverse effects. [17, 18] However, it is unclear whether MES+HS treatment has a positive effect on pathological skin condition.
Here, we investigated the effect of MES+HS on psoriasis using the imiquimod-induced psoriasis mouse model. MES+HS treatment reduced skin hyperplasia in imiquimod-treated mice. Furthermore, MES+HS improved the inflammatory symptoms in skin lesion, indicating the potential usefulness of MES+HS as novel modality for psoriasis.
| MATERIAL S AND ME THODS

| Animals
Seven-week-old female C57BL/6J mice (Charles River Laboratories, Inc., Kanagawa, Japan) were bred in individual cages. 
| In vivo MES+HS treatment
Mice were treated with MES and/or HS for 10 min daily as previously described. [13, 14] In short, mice were placed in well-ventilated chamber attached with electro-conductive and thermo-generative rubber electrodes and treated with 12 V (55 pulses per second (pps)) of direct current with individual pulse duration of 0.1 mseconds.
The condition of heat shock treatment was 42°C at the surface of electrodes.
| Cell culture and in vitro MES+HS treatment
Human immortalized keratinocytes (HaCaT cells) were maintained in DMEM containing 10% foetal bovine serum and 100 units/mL penicillin G and 100 μg/mL streptomycin. Prior to IL-17A stimulation, cells were cultured in 6-well plates and grown to 50%-60% confluence.
Cells were incubated with 100 ng/mL recombinant IL-17A (R&D systems) for a total of 48 h and treated with MES (1 v/cm, 55 pps, 0.1 mseconds) and HS (42°C) for 10 minutes. MES+HS treatment was performed as previously described. [13, 14] Briefly, carbon electrode (IonOptix) was attached to cell culture plates and connected to a function generator (WF1973; NF Corporation, Yokohama, Japan).
The function generator was adjusted to deliver 1 V/cm (55 pps) of direct current with individual pulse duration of 0.1 mseconds. For simultaneous heat shock treatment, cell culture plate was sealed and soaked in water bath at 42°C while MES was ongoing.
| Histological and immunohistochemical analyses
Skin samples were fixed in 10% paraformaldehyde and embedded in paraffin. For haematoxylin and eosin (H&E) staining, 6-μm tissue sections were stained with H&E. Average epidermal thickness was quantified using ImageJ software, National Institute of Health (NIH), Maryland, USA. For immunohistochemical analysis, antigen retrieval was first performed using Dako REAL Target Retrieval Solution (Dako, Santa Clara, CA, USA) at 98°C for 40 minutes and then sections were incubated with anti-PCNA (PC10, Dako) and anti-CD3 (ab16669, Abcam, Cambridge, UK) antibodies followed by the secondary antibody. After incubation, DAB and AEC reactions were performed for 10 minutes. All images were acquired using Bio-Revo imaging (BX-X700; KEYENCE, Osaka, Japan). For quantification of CD3-positive cells in epidermis, four sections of each sample were randomly taken and analyzed by three researchers.
| Real-time quantitative RT-PCR analysis (Q-PCR)
Total RNA was extracted with RNAiso Plus (Takara, Shiga, Japan).
Real-time quantitative RT-PCR was performed using PrimeScript ™ RT Reagent Kit and SYBR ® Premix ExTaq ™ II (Takara). The primer pairs used for quantitative RT-PCR are listed in Table S1 . 
| Immunoblotting analysis and enzyme-linked immunosorbent assay (ELISA)
Protein
| Statistics
Data are presented as mean ± SE. Normally distributed variables
were assessed with Student's t test, and non-normally distributed variables were compared by Mann-Whitney U test or Steel's test. P value <0.05 was considered statistically significant.
| RE SULTS
| MES+HS treatment reduced skin hyperplasia in imiquimod-induced psoriasis mouse model
We used imiquimod-induced psoriasis mouse model to determine the effect of MES+HS on psoriasis pathology. Imiquimod is an agonist of Toll-like receptor (TLR) 7 and causes psoriasis-like skin inflammation. [19] Imiquimod was applied to mice ear, and mice were In addition, MES+HS treatment significantly lowered the mRNA expression of Krt6a, a keratinocyte proliferation marker ( Figure 1E ).
However, MES+HS treatment did not rescue the mRNA expression of loricrin, a keratinocyte late differentiation marker ( Figure 1F ).
Collectively, these data showed that MES+HS ameliorates abnormal keratinocyte proliferation in imiquimod-treated mice.
| MES+HS treatment reduced the mRNA expression of Reg3γ which promotes keratinocyte hyperproliferation
We investigated whether MES+HS affects the expression of proliferation-related molecule. In inflammatory skin, Reg3 strongly induces keratinocyte proliferation via Akt signaling. [6, 20] MES+HS treatment significantly suppressed the mRNA expression of Reg3γ Taken together, these results suggest that MES+HS ameliorates skin hyperplasia likely via decreasing the mRNA expression of Reg3γ.
| MES+HS treatment decreased the expression of inflammatory cytokines
Next, we checked whether MES+HS has a beneficial effect on in- These results suggest that MES+HS reduces the excessive immune response in skin lesion.
| MES+HS decreased the expression of antimicrobial molecules
We demonstrated in a previous study that MES+HS treatment ameliorated the sterile inflammation in chronic kidney disease mouse model via activating some signaling pathways. [14] In particular, we confirmed that MES+HS treatment activates AMPK in various types of cells. [12, 16] In imiquimod-treated skin, MES+HS significantly activated AMPK ( Figure 4A,B) . Consistently, in IL-17A-stimulated HaCaT cell, MES+HS treatment had synergistic effect on activation of AMPK ( Figure 4C) . Interestingly, several studies showed that the activation of AMPK suppresses the inflammatory cytokine responses. [21, 22] Based on these findings, we checked whether MES+HS treatment reduces keratinocyte inflammation. We confirmed that the mRNA expression of S100A8, which aggravates psoriasis, was lowered in MES+HS-treated mice (P = 0.07; Figure 4D ) albeit not statistically significant. Next, we treated the IL-17A-stimulated HaCaT cells with MES+HS for 10 minutes. IL-17A treatment increased the mRNA expression of S100A8, S100A9 and β-defensin2. In MES+HS-treated cells, these mRNA expressions were significantly decreased ( Figure 4E-G) . Taken together, our results showed that MES+HS treatment directly improves keratinocyte inflammation.
F I G U R E 2 MES+HS Lowered the mRNA Expression of Reg3γ
Which Promotes Keratinocyte Hyperproliferation. A, mRNA from skin of right and left ears of mice was analyzed. The level of mRNA was normalized to the level of GAPDH mRNA (internal control). Data are presented as mean ± SE (n = 6 per group). *P < 0.05 vs control, #P < 0.05 vs imiquimod; Student's t test. B and C, Ear skin tissues were subjected to immunoblotting analysis using the indicated antibodies. Actin was used as control. D, Relative amount of p-Akt (Ser473) in (C) was normalized to total Akt and quantified. Data are presented as mean ± SE (n = 4, 6 per group). *P < 0.05 assessed by Student's t test 
| D ISCUSS I ON
Modulation of inflammation is effective in the treatment of psoriasis.
In this study, imiquimod-treated mice had remarkably high mRNA expression level of several inflammatory cytokines (Il-1β, Il-6, Il-8, Il-17A, ; in particular, the protein expression of IL-17A was 17.7 times higher than that of control ( Figure 3A,B) . IL-17A is mainly released from T lymphoid cells and activates the intracellular signaling pathways in various types of cells such as epithelial and endothelial cells and macrophages. [23] Importantly, MES+HS-treated pathological skin had decreased expression of IL-17A ( Figure 3A,B) .
Moreover, MES+HS treatment significantly reduced the mRNA expression of Il-22 by more than half ( Figure 3A) . Therefore, MES+HS may have immunosuppressive effect on these cytokine-producing cells. Because IL-17A inhibitors have high therapeutic effect on psoriasis in clinical trials, [24] IL-17A could be an important target of MES+HS treatment. In relation to this, previous study showed that IL-17A increases the expression of inflammatory molecules such as antimicrobial molecules in the skin. [25] In IL-17A-treated HaCaT cells, MES+HS treatment significantly decreased the expression of antimicrobial molecules (S100A8, S100A9 and β-defensin2) (Figure 4 ). We previously showed that MES+HS treatment ameliorates insulin resistance through the activation of phosphatidylinositol-3 kinase (PI3K)/Akt pathway. [13] However, in the context of psoriatic skin hyperproliferation, we consider that the down-regulation of Akt activators including Reg3γ by MES+HS probably contributed to the decrease in the expression of Akt in MES+HS-treated mice.
For improving inflammatory skin disorders, topical steroids are frequently used. A recent study has shown that clobetasol propionate, which is one of the most potent corticosteroids, has strong anti-inflammatory effect on imiquimod-induced psoriasis-like mouse model. [21] On the other hand, MES+HS treatment improved imiquimod-induced psoriasis moderately. We consider that the com- effect on metabolic abnormality. [17] Recently, epidemiological studies have shown that psoriasis is related to several chronic diseases including cardiovascular disease, obesity and diabetes. [26] Psoriasis comorbidities accelerate the pathology of psoriasis. [27] These comorbidities involve systemic inflammation and cause the dysregulation of skin immunity. If complications arise, an increase in the expression of TNF-α stimulates the immune cells and progresses the pathology of psoriasis. [28] Furthermore, the deficiency of adiponectin exacerbates skin inflammation in imiquimod-induced psoriasis mice model. [29] Because F I G U R E 4 MES+HS Decreased the Expression of Antimicrobial Molecules. A and B, Ear skin tissues were subjected to immunoblotting analysis using the indicated antibodies. Actin was used as control. B, Relative amount of p-AMPK (Thr172) in (A) was normalized to total AMPK and quantified. Data are presented as mean ± SE (n = 3 per group). *P < 0.05 assessed by Mann-Whitney U test. C, Human keratinocyte cell line HaCaT cells were stimulated with 100 ng/mL recombinant IL-17A for 48 h. After 43 h from treatment, cells were treated with MES+HS for 10 min. After 5 h, cells were subjected to immunoblotting analysis using the indicated antibodies. Actin was used as control. D, mRNA from skin of right and left ears of mice was analyzed. The level of mRNA was normalized to the level of GAPDH mRNA (internal control). Data are presented as mean ± SE (n = 6 per group). *P < 0.05, **P < 0.01 vs control; Student's t test; n.s., not significant. E-G, HaCaT cells were stimulated with recombinant IL-17A and then treated with MES+HS. Total RNA was extracted and subjected to quantitative RT-PCR. The levels of mRNA were normalized to the level of actin mRNA (internal control). Data are presented as mean ± SE (n = 3 per group). *P < 0.05 vs control, #P < 0.05 vs IL-17A; Mann-Whitney U test MES+HS treatment can ameliorate the dysregulation of the gene expressions in metabolic diseases, it can be useful to regulate both skin inflammation and psoriasis comorbidities. In conclusion, MES+HS treatment ameliorates the pathology of psoriasis in imiquimodtreated mice model. MES+HS therapy may be effective in restraining the progression of psoriasis. 
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